Oragenics Reports Governance Changes and New Agreements
Ticker: OGEN · Form: 8-K · Filed: Jan 17, 2025 · CIK: 1174940
Sentiment: neutral
Topics: governance, management-change, agreement
Related Tickers: OGEN
TL;DR
Oragenics shakes up board, appoints new execs, and signs new deals.
AI Summary
On January 15, 2025, Oragenics, Inc. reported a material definitive agreement, the departure of directors or certain officers, and the election of directors. The company also announced the appointment of certain officers and compensatory arrangements. This filing indicates significant corporate governance changes and potential strategic shifts within Oragenics, Inc.
Why It Matters
Changes in board composition and executive appointments can signal shifts in company strategy, operational focus, or financial direction, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Material definitive agreements and changes in board/officer composition often carry inherent risks related to execution, integration, and strategic alignment.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- January 15, 2025 (date) — Date of earliest event reported
FAQ
What specific material definitive agreement was entered into by Oragenics, Inc. on January 15, 2025?
The filing indicates a material definitive agreement was entered into, but the specific details of this agreement are not provided in the provided text.
Who are the directors or officers that have departed from Oragenics, Inc. as of January 15, 2025?
The filing states the departure of directors or certain officers, but does not name the individuals involved in the provided text.
Who has been elected as a director to the Oragenics, Inc. board?
The filing mentions the election of directors, but does not specify the names of the newly elected directors in the provided text.
Are there any new officers appointed at Oragenics, Inc. as of January 15, 2025?
Yes, the filing indicates the appointment of certain officers.
What is the nature of the compensatory arrangements for certain officers mentioned in the filing?
The filing notes compensatory arrangements for certain officers, but the specific details of these arrangements are not elaborated upon in the provided text.
Filing Stats: 722 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2025-01-17 16:05:18
Key Financial Figures
- $275,000 — iii) increase her base salary by 10% to $275,000; and (iv) change her location to Saraso
- $75,000 — scretionary cash bonus in the amount of $75,000. Item 8.01 OTHER INFORMATION. All
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex10-1.htm (EX-10.1) — 129KB
- ex10-2.htm (EX-10.2) — 23KB
- 0001493152-25-002751.txt ( ) — 407KB
- ogen-20250115.xsd (EX-101.SCH) — 3KB
- ogen-20250115_lab.xml (EX-101.LAB) — 33KB
- ogen-20250115_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
01
Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT On January 16, 2025, the Board of Directors (the "Board") of Oragenics, Inc. (the "Company") appointed Ms. Janet Huffman, the Company's Chief Financial Officer and Interim Principal Executive Officer, to also serve as the Company's Interim Chief Executive Officer effective as of January 16, 2025, and in connection therewith, the Board of Directors determined that, effective January 16, 2025, Ms. Huffman's employment agreement would be modified to (i) include her new title of Interim Chief Executive Officer; (ii) require that as she report directly to the Company's Board of Directors and its Executive Chairman; (iii) increase her base salary by 10% to $275,000; and (iv) change her location to Sarasota (given the Company relocation from Tampa to Sarasota). All other terms of Ms. Huffman's Employment Agreement remain in full force and effect. The foregoing summary is qualified in its entirety by the specific terms of the First Amendment to Employment Agreement attached as Exhibit 10.2 to this Form 8-K which is incorporated herein by reference.
02
Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. (a) Resignation of Director. On January 15, 2025, Mr. Bruce Cassidy resigned as director of the Company to pursue other opportunities. Mr. Cassidy's resignation was not due to any disagreement with the Company on any matter related to its operations, policies or practices. ( e) Compensatory Arrangements of Certain Officers. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Additionally, on January 16, 2025, the Board also determined to grant Ms. Huffman a discretionary cash bonus in the amount of $75,000.
01
Item 8.01 OTHER INFORMATION. All of the Pre-Funded Warrants issued in connection with the Company's September 2024 Offering have been exercised as of the date hereof. As a result, the Company has 13,709,805 shares of Common Stock Issued and Outstanding as of January 16, 2025.
FINANCIAL STATEMENTS AND EXHIBITS
FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit No. Description 10.1 Executive Employment Agreement between the Company and Janet Huffman dated effective March 8, 2023. 10.2 Amendment to Executive Employment Agreement between the Company and Janet Huffman dated effective January 16, 2025. 104 Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL)
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 17 th day of January 2025. ORAGENICS, INC. (Registrant) BY: /s/Janet Huffman Janet Huffman Chief Financial Officer